KR20230051118A - 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 - Google Patents

암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 Download PDF

Info

Publication number
KR20230051118A
KR20230051118A KR1020227037223A KR20227037223A KR20230051118A KR 20230051118 A KR20230051118 A KR 20230051118A KR 1020227037223 A KR1020227037223 A KR 1020227037223A KR 20227037223 A KR20227037223 A KR 20227037223A KR 20230051118 A KR20230051118 A KR 20230051118A
Authority
KR
South Korea
Prior art keywords
pyridyl
amino
triazolo
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037223A
Other languages
English (en)
Korean (ko)
Inventor
길스 알버트 브라운
마일스 스튜어트 콘그리브
크리스틴 마리 리차드슨
레베카 폴
스테펜 필립 앤드류
조나단 스테펜 메이슨
프란체스카 데플로리언
니겔 앨런 스웨인
Original Assignee
헵테얼즈 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헵테얼즈 테라퓨틱스 리미티드 filed Critical 헵테얼즈 테라퓨틱스 리미티드
Publication of KR20230051118A publication Critical patent/KR20230051118A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227037223A 2020-03-26 2021-03-25 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 Pending KR20230051118A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994970P 2020-03-26 2020-03-26
US62/994,970 2020-03-26
PCT/EP2021/057807 WO2021191379A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Publications (1)

Publication Number Publication Date
KR20230051118A true KR20230051118A (ko) 2023-04-17

Family

ID=75339741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037223A Pending KR20230051118A (ko) 2020-03-26 2021-03-25 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물

Country Status (8)

Country Link
US (1) US12528815B2 (https=)
EP (1) EP4126873A1 (https=)
JP (1) JP7774573B2 (https=)
KR (1) KR20230051118A (https=)
CN (1) CN115867280B (https=)
AU (1) AU2021243725A1 (https=)
CA (1) CA3177056A1 (https=)
WO (1) WO2021191379A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof

Also Published As

Publication number Publication date
CN115867280B (zh) 2025-05-27
CA3177056A1 (en) 2021-09-30
US12528815B2 (en) 2026-01-20
JP7774573B2 (ja) 2025-11-21
JP2023519361A (ja) 2023-05-10
EP4126873A1 (en) 2023-02-08
CN115867280A (zh) 2023-03-28
AU2021243725A1 (en) 2022-10-27
WO2021191379A1 (en) 2021-09-30
US20230146483A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CN114901664B (zh) 吡啶酮化合物及应用
TWI609868B (zh) 雜芳基吡啶酮及氮雜吡啶酮化合物
CA2927252C (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
JP6430512B2 (ja) リジン特異的デメチラーゼ−１の阻害剤
KR102272792B1 (ko) Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
EP3036229A1 (en) Alkynyl alcohols and methods of use
TW201127385A (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
CA3142340A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP2531498B1 (en) Compounds and compositions as protein kinase inhibitors
TW202509031A (zh) Ｃｄｋ抑制劑萘啶化合物
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
TW202023559A (zh) 吡化合物及其用途
EP4327877A2 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TW202421628A (zh) 用於治療癌症之方法
KR20140139023A (ko) 암을 치료하기 위한 6-(4-(1-아미노-3-하이드록시사이클로부틸)페닐)-5-페닐(퓨로, 싸이에노 또는 피롤로)[2,3-d]피리미딘-4-온 유도체
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
JP7675094B2 (ja) トリアゾロン化合物
CA3113732C (en) Aromatic heterocyclic compound with kinase inhibitory activity
WO2021156439A1 (en) Triazole compounds as adenosine receptor antagonists
JP7709454B2 (ja) トリアゾロン化合物
RU2772226C2 (ru) Новые производные оксоизохинолина
CN121773105A (zh) Cbl-b抑制剂及其应用
TWI690528B (zh) 稠環雙環吡啶基衍生物
HK1225378A1 (en) Alkynyl alcohols and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902